Dublin, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The "Emerging Infectious Disease Diagnostics Market - A Global and Regional Analysis: Focus on Application, Technology, Type of Infection, Disease Type, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The global emerging infectious disease diagnostics market was valued at $19.56 billion in 2022 and is expected to reach $37.21 billion by 2033, growing at a CAGR of 6.19% between 2023 and 2033
The global market for emerging infectious disease diagnostics is experiencing significant growth due to several key factors. These include the substantial economic burden posed by infectious diseases, government support through funding and collaborative efforts, rising demand for point-of-care and syndromic testing, and continuous technological advancements in the field of molecular diagnostics.
The emergence of the COVID-19 pandemic has had a profound and far-reaching impact on infectious disease diagnostics worldwide. The urgent need for extensive testing to identify and control the spread of the virus has led to a rapid expansion of diagnostic capabilities.
The pandemic prompted an unprecedented surge in the development and deployment of diagnostic tests, particularly nucleic acid-based tests like PCR and antigen tests, designed to detect SARS-CoV-2, the virus responsible for COVID-19. Additionally, the outbreak accelerated advancements in point-of-care testing technologies, including rapid antigen tests and molecular diagnostics, thereby enabling quicker and more accessible testing.
Furthermore, the COVID-19 crisis underscored the critical importance of surveillance systems, data sharing mechanisms, and digital health technologies in monitoring and responding to infectious diseases. The valuable lessons learned from the pandemic are expected to have a lasting impact on the infectious disease diagnostics field, stimulating innovations, enhancing testing capabilities, bolstering rapid response readiness, and fostering global collaboration.
The top segment players who are leading include manufacturers offering tests leveraging polymerase chain reaction (PCR) technology, which captured around 42.35% of the presence in the market in 2022. This was followed by immunodiagnostics at 30.75% market share in 2022.
North America, encompassing both the United States and Canada, currently holds the largest share in the global emerging infectious disease diagnostics market. This growth in North America is primarily driven by factors such as the presence of a substantial number of diagnostic companies and a well-established laboratory infrastructure capable of conducting advanced molecular diagnostic tests.
Market Segmentation
Point-of-Care Testing to Register Significant Growth during the Forecast Period 2023-2033
Point-of-care (POC) testing for infectious diseases offers rapid and on-site diagnostic capabilities, enabling immediate detection and decision-making.
They provide quick results, often within minutes or hours, facilitating timely diagnosis and treatment decisions, particularly crucial for infectious diseases where early intervention can significantly impact patient outcomes and prevent further transmission.
POC tests are particularly useful in developing countries where there is a lack of robust laboratory infrastructure or high-end capital equipment to conduct diagnostic tests. They can help in the timely and accurate diagnosis of diseases in low-resource settings, thereby aiding in relieving the burden of infectious diseases in the region.
Next-Generation Sequencing (NGS) to Register Maximum Growth in the Market
Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.
Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).
Bacterial and Viral Infections to Dominate the Market
Bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.
Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.
Respiratory Infections to Dominate the Market Majorly Driven by the COVID-19 Pandemic
A vast majority of molecular diagnostic companies offer tests for testing various kinds of bacteria and viruses responsible for causing respiratory infections.
Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as RT-PCR and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus at once in a single assay.
Hospitals and Clinics Continue to Dominate the Market
Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing.
In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 284 |
| Forecast Period | 2023 - 2033 |
| Estimated Market Value (USD) in 2023 | $20.41 Billion |
| Forecasted Market Value (USD) by 2033 | $37.21 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
Market Outlook
Market Overview
- Timeline of Emerging Technologies for Infectious Disease Diagnostics
- Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
- Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
- Current Market Landscape of Emerging Infectious Disease Diagnostics
- Future Potential
- CRISPR
- NGS
- INAAT
- Digital PCR (dPCR)
Drivers
- Economic Burden of Infectious Diseases
- Government Support to Advance Research and Facilitate Early Diagnosis of Infectious Diseases Through Funding and Collaboration
- Increasing Demand for Point-of-Care (POC) and Syndromic Testing
- Technological Advancements in Molecular Diagnostics
- Isothermal Nucleic Acid Amplification Techniques (INAATs)
- Digital PCR
- CRISPR Technologies
Restraints
- Poor Reimbursement for Molecular Diagnostic Tests for Infectious Diseases
- Erratic Trend in Infectious Disease Epidemic Outbreaks Globally
- Lack of an Established Framework for NGS-based Tests for Infectious Diseases
Opportunities
- Potential of Molecular Diagnostic Tests in Low-Resource Settings
- Potential of Rapid Point-of-Care Tests in Managing Antimicrobial Resistance
Key Companies Profiled:
- Abbott Laboratories
- Becton, Dickinson and Company
- bioMerieux S.A.
- Bio-Rad Laboratories, Inc.
- Co-Diagnostics, Inc.
- DANAHER CORPORATION
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd
- Hologic, Inc.
- QIAGEN N.V.
- QuidelOrtho Corporation
- T2 Biosystems, Inc.
- Tecan Trading AG
- Thermo Fisher Scientific Inc.
- Siemens Healthineers AG
For more information about this report visit https://www.researchandmarkets.com/r/6fctfa
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
